Autoimmune Encephalitis symptomatic and supportive therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis requires symptomatic and supportive treatment alongside immunotherapy and treatment of an associated tumor. Care aims to control seizures and distress, prevent complications, and restore function. Symptomatic improvement alone does not establish that inflammation has resolved.[1]
For disease-directed treatment, see medical therapy.
Seizures and Status Epilepticus
Autoimmune encephalitis-associated seizures generally require antiseizure medicines together with prompt immunotherapy. Drug choice should account for seizure type, behavioral adverse effects, interactions, and organ function. After recovery, continued antiseizure treatment should be individualized; not every patient requires lifelong treatment.[2]
Autoimmune encephalitis with status epilepticus requires emergency treatment and escalation according to established seizure protocols. Continuous electroencephalography (EEG) is useful when consciousness remains impaired after seizures, nonconvulsive seizures are suspected, or intravenous anesthetic treatment requires monitoring. Video-EEG can help distinguish seizures from dyskinesias and autonomic spells; clinical appearance alone may be misleading.[3]
Agitation, Psychosis, and Catatonia
Autoimmune encephalitis-related behavioral disturbance should be managed with a calm environment, reduced overstimulation, familiar caregivers, and assessment for pain, infection, medication effects, and sleep disruption. Minimize physical restraint when feasible.[2]
- Antipsychotics: Use cautiously, particularly in N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis. Worsening movements, rigidity, fever, or autonomic instability requires reassessment for adverse drug reactions, including neuroleptic malignant syndrome.
- Catatonia: Benzodiazepines may help, but require caution with hypoventilation or reduced alertness. Severe refractory catatonia may warrant electroconvulsive therapy through specialist psychiatry, neurology, and anesthesia assessment.[2]
Movement Disorders, Sleep, and Mood
Autoimmune encephalitis-related movement disorders may need targeted treatment when they cause injury, pain, exhaustion, or interfere with care. Balance benefit against sedation and respiratory effects. Restore a regular sleep–wake schedule and address persistent insomnia, anxiety, depression, or emotional lability. Symptomatic drugs should be reviewed as recovery progresses.[1]
Autonomic and Respiratory Support
Autoimmune encephalitis can cause central hypoventilation, impaired airway protection, and major fluctuations in heart rate, blood pressure, and temperature. Severe cases require intensive care, respiratory support, and continuous physiological monitoring. Clinically important bradyarrhythmias or asystole require urgent specialist management. Sedatives may worsen breathing and obscure neurological assessment.[4]
Fluids, Electrolytes, and General Care
Autoimmune encephalitis care includes monitoring fluid balance and electrolytes. Hyponatremia is particularly associated with leucine-rich glioma-inactivated protein 1 (LGI1) antibody encephalitis. Evaluate the cause and correct safely; avoid rapid overcorrection.[4]
Autoimmune encephalitis with dysphagia, reduced consciousness, or immobility requires individualized multidisciplinary care:
- Assess swallowing and aspiration risk; provide appropriate nutritional support.
- Review venous thromboembolism prevention, skin care, positioning, and mobilization.
- Identify infections, urinary or bowel problems, and pain that may worsen agitation or delay recovery.[4][1]
Rehabilitation and Follow-Up
Autoimmune encephalitis recovery may require physical, occupational, speech and language, psychological, and neuropsychological rehabilitation. Assess memory, attention, executive function, fatigue, mood, and daily independence. Plan a gradual return to work or education and discuss driving according to local rules.[1]
Autoimmune encephalitis in children may leave cognitive and fatigue-related difficulties despite good physical recovery. Coordinate school support with caregivers and teachers; educational demands can reveal persistent deficits.[5] The pediatric NMDAR consensus emphasizes rehabilitation in a service familiar with acquired brain injury; improvement may continue for two years or longer.[6]
Reassessment and Evidence Limitations
Autoimmune encephalitis-related deterioration should prompt reassessment for relapse, seizures, infection, metabolic disturbance, and treatment toxicity. Much symptomatic treatment rests on expert consensus and observational evidence; management must be adapted to the patient rather than a fixed drug sequence.[2][1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Abboud H, Probasco J, Irani SR, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.
- ↑ 2.0 2.1 2.2 2.3 Hahn C, Budhram A, Alikhani K, et al. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.
- ↑ Herman ST, Abend NS, Bleck TP, et al. Consensus statement on continuous EEG in critically ill adults and children, part I: indications. J Clin Neurophysiol. 2015;32(2):87–95. doi:10.1097/WNP.0000000000000166. PMID:25626778.
- ↑ 4.0 4.1 4.2 Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.
- ↑ de Bruijn MAAM, Aarsen FK, van Oosterhout MP, et al. Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. Neurology. 2018;90(22):e1997–e2005. doi:10.1212/WNL.0000000000005605. PMID:29703768.
- ↑ Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.